EG 427 appoints Ralph Laufer as new member to Board of Directors

May 09, 2023

Biotech and pharmaceutical industry veteran, Ralph Laufer, Ph.D., joins the Board of Directors as an independent member.

EG 427 is adding complementary expertise among its Board directors to support its ambitions.

 

Read full Press Release in English or in French


Recent posts

EG 427 Announces Attendance at Conferences in H1 2024
EG 427 Announces Attendance at Conferences in H1 2024

read more >

EG 427 Announces New Preclinical Results from Multiple Studies of EG110A  in NDO and OAB
EG 427 Announces New Preclinical Results from Multiple Studies of EG110A in NDO and OAB

read more >

EG 427 Appoints Don Haut, Ph.D as Chief Business Officer and Opens US Headquarters
EG 427 Appoints Don Haut, Ph.D as Chief Business Officer and Opens US Headquarters

read more >

EG 427 Announces Positive Preclinical Results from EG110A IND-Enabling Study in Neurogenic Detrusor Overactivity and Overactive Bladder
EG 427 Announces Positive Preclinical Results from EG110A IND-Enabling Study in Neurogenic Detrusor Overactivity and Overactive Bladder

read more >

EG 427 to hold poster presentation on lead asset EG110A at ESGCT
EG 427 to hold poster presentation on lead asset EG110A at ESGCT

read more >

×

Essential Cookies

These cookies are necessary for the website to function and cannot be turned off. They are used, for example, to maintain the contents of the user's basket. You can set your browser to block these cookies, but then the website will not function prope

Always active

Analytical cookies

These cookies allow you to count visits and traffic sources. Thanks to these files, it is known which pages are more popular and how the website visitors navigate. All information these cookies collect is anonymous.